Related Experiment Videos
Insulin lispro: a fast-acting insulin analog
S L Noble1, E Johnston, B Walton
1University of Mississippi Medical Center, Jackson, USA.
American Family Physician
|February 11, 1998
Summary
Insulin lispro, a short-acting insulin analog, offers faster absorption and quicker action compared to regular human insulin. Its safety profile and side effect rates are comparable to traditional insulins for type 1 diabetes management.
Area of Science:
- Endocrinology
- Metabolic Disorders
- Pharmacology
Background:
- Maintaining near-normal blood glucose is crucial for type 1 diabetes management.
- Regular short-acting insulins have limitations in absorption and peak action.
- Short-acting insulin analogs aim to improve glycemic control.
Purpose of the Study:
- To evaluate the pharmacokinetic and safety profile of insulin lispro.
- To compare insulin lispro with regular human insulin in patients with type 1 diabetes.
Main Methods:
- Subcutaneous administration of insulin lispro.
- Assessment of absorption, peak levels, and duration of activity.
- Comparison of adverse event rates with regular human insulin.
Main Results:
- Insulin lispro demonstrated faster subcutaneous absorption and earlier, greater insulin peak.
- Peak insulin levels occurred 30-90 minutes post-administration, with duration less than five hours.
- Insulin lispro showed similar rates of allergy, lipodystrophy, hypoglycemia, and abnormal lab results compared to regular human insulin.
Conclusions:
- Insulin lispro offers an improved pharmacokinetic profile over regular human insulin.
- Insulin lispro is a safe and effective alternative for type 1 diabetes management.
- The comparable safety profile supports the use of insulin lispro for better glycemic control.